Synopsis: Manipal Health Enterprises has received SEBI approval for its ₹8,000 crore IPO, paving the way for its stock market debut. The issue includes a fresh share sale and offer for sale by investors. Proceeds will support debt repayment, acquisitions, and growth plans, with leading banks managing the public offering.
Manipal Health Enterprises Ltd, a Bengaluru-based healthcare company, has received approval from the Securities and Exchange Board of India (SEBI) for its initial public offering (IPO). The company had filed its IPO papers with SEBI on March 25, 2026.
The SEBI approval moves Manipal Health Enterprises closer to its stock market debut, representing a significant milestone in its fundraising journey and future expansion plans as it prepares to enter the public markets.
IPO Structure and Share Sale
The proposed IPO of Manipal Health Enterprises includes a fresh issue of shares worth up to Rs. 8,000 crore, along with an offer for sale (OFS) of up to 43,227,668 equity shares. The OFS will involve shares held by promoters Imperius Healthcare Investments Pte. Ltd. and Manipal Education and Medical Group India Private Limited.
The selling shareholders include TPG SG Magazine Pte. Ltd, Seventy Second Investment Company LLC, Ammar Sdn Bhd, Novo Holdings Invest Asia A/S, and Phoenix Bear Investments, LLC. The OFS will allow existing investors to reduce their stakes through the public issue.
Use of IPO Proceeds
Manipal Health Enterprises plans to use Rs. 5,378 crore from the fresh issue proceeds to repay or prepay, fully or partially, certain outstanding borrowings and accrued interest of its material subsidiary, Manipal Hospitals Private Ltd.
The company will also allocate Rs. 574 crore towards acquiring a minority stake in its step-down subsidiary, Sahyadri Hospitals Private Limited, along with meeting general corporate requirements.
Pre-IPO Placement and Lead Managers
Manipal Health Enterprises may consider a pre-IPO placement of up to Rs. 1,600 crore in consultation with its book-running lead managers. If completed, the placement proceeds will reduce the size of the fresh issue in the upcoming IPO.
Leading financial institutions, including Kotak Mahindra Capital, Axis Capital, Goldman Sachs, Jefferies, J.P. Morgan, UBS, and DBS Bank, have been appointed as book-running lead managers for Manipal Health Enterprises’ proposed IPO. The appointed managers will oversee key IPO-related processes, including coordination and execution of the public offering.
Manipal Health’s Expanding Healthcare Network
Manipal Health Enterprises Limited (Manipal Hospitals) is the second-largest healthcare network in India, headquartered in Bengaluru. It is backed by Singapore’s state-owned Temasek as its majority stakeholder. The company delivers high-value tertiary and quaternary care, specializing heavily in oncology, cardiology, neurosciences, orthopaedics, and organ transplants.
Manipal Health is among India’s largest hospital chains, operating 38 hospitals with over 12,300 beds across 14 states and union territories as of September 2025. The company continues to expand its healthcare footprint, and on a pro forma basis, its network increases to 48 hospitals across the country.
Financial Performance
Manipal Health reported strong financial performance for the six months ended September 2025, recording a net profit of Rs. 571.8 crore. During the same period, the company generated revenue of Rs. 4,713 crore, reflecting its growing operational scale and strong position in India’s healthcare services market.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
